Safety And Target Engagement Of Clu1 By Valproic Acid In Subjects With Intact Cognition: Proof Of Concept For The Development Of A Prevention Trial For Alzheimer's Disease.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Valproic acid (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions
- 09 Oct 2019 Biomarkers information updated
- 23 Jul 2013 Planned End Date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 21 Dec 2012 New trial record